Warm autoantibodies: time for a change by Nobles, J. Ryan & Wong, Clare
IMMUNOHEMATOLOGY, Volume 29, Number 1, 2013 5
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Routine adsorption procedures to remove autoantibodies from 
patients’ serum often require many hours to perform. This time-
consuming process can create significant delays that affect patient 
care. This study modified the current adsorption method to 
reduce total adsorption time to 1 hour. A ratio of one part serum 
to three parts red blood cells (RBCs; 1:3 method) was maintained 
for all samples. The one part serum was split into three tubes. 
Each of these three aliquots of serum was mixed with one full part 
RBCs, creating three adsorbing tubes. All tubes were incubated 
for 1 hour with periodic mixing. Adsorbed serum from the three 
tubes was harvested, combined, and tested for reactivity. Fifty-
eight samples were evaluated using both the current method 
and the 1:3 method. Forty-eight (83%) samples successfully 
adsorbed using both methods. Twenty (34.5%) samples contained 
underlying alloantibodies. The 1:3 method demonstrated the 
same antibody specificities and strengths in all 20 samples. 
Eight samples failed to adsorb by either method. The 1:3 method 
found previously undetected alloantibodies in three samples. Two 
samples successfully autoadsorbed but failed to alloadsorb by 
either method. The 1:3 method proved to be efficient and effective 
for quick removal of autoantibodies while allowing for the 
detection of underlying alloantibodies. Immunohematology 
2013;29:5–10.
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Red blood cell (RBC) autoantibodies, when present in the 
serum of a patient, will react with the patient’s RBCs as well as 
with all normal RBCs. These autoantibodies have the potential 
of masking the presence of underlying clinically significant 
alloantibodies. When a patient with warm autoantibodies 
in the serum is in urgent need of an RBC transfusion, the 
time-intensive adsorption process to remove autoantibodies 
can adversely impact patient care. The current published 
adsorption procedure1 (current method) used by reference 
laboratories and transfusion services can require 4 to 6 hours 
to complete and is not guaranteed to successfully remove the 
autoantibodies.
A less time-consuming alternative is needed to expedite 
the adsorption process and, at the same time, effectively remove 
the warm autoantibodies. One method would be to increase 
the RBC-to-serum ratio in an attempt to more effectively 
remove autoantibodies. Increasing the ratio of RBCs provides 
more antigen sites to adsorb the autoantibodies; however, this 
method has been reported to cause dilution of the serum.1
This study evaluated a modified, less time-consuming 
adsorption procedure that could potentially yield results 
comparable to those produced by the current method. The 
modified adsorption procedure involved adjusting the initial 
serum-to-RBC volumes to a 1:3 ratio (1:3 method) and 




A total of 58 patient samples known to contain warm 
autoantibodies were obtained at random. Samples were 
required to have exhibited autoantibody reactivity and to have 
had either autologous or allogeneic adsorptions performed 
using current methods. Three types of samples were used for 
comparison testing: (1) those that successfully autoadsorbed or 
alloadsorbed and demonstrated no underlying alloantibodies; 
(2) those that successfully autoadsorbed or alloadsorbed and 
demonstrated underlying alloantibodies; and (3) those that 
did not successfully autoadsorb or alloadsorb and required 
allogeneic adsorption using 20 percent polyethylene glycol 
(PEG) prepared in-house (Sigma-Aldrich, St. Louis, MO).
Ficin Treatment of Adsorbing Cells
Ficin-treated allogeneic RBCs for warm adsorption were 
selected to match the patient’s Rh, K, Kidd, and Ss phenotype. 
The volume of RBCs was determined accordingly to yield the 
required volume; a 3-mL aliquot was generally used. RBCs were 
obtained from designated “adsorbing units.” The adsorbing 
RBCs were washed once with 0.9 percent normal saline in 
a large 16 × 100-mm test tube. The tube was centrifuged to 
pack the cells, and as much supernatant saline was removed 
as possible. The washed cells were treated with 1 percent ficin 
prepared in-house (MP Biomedicals, Solon, OH) in the ratio 
of 0.5 mL of ficin to 1 mL of cells. The tube was mixed several 
times by inversion and incubated at 37°C for 15 minutes with 
periodic mixing. The cells were washed three times with large 
volumes of saline. For the last wash, the tube was centrifuged 
for 10 minutes without a centrifuge brake to avoid disturbing 
the RBC-saline interface. As much supernatant saline as 
possible was removed to prevent subsequent dilution of serum.
RepoRt
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Adsorption Using the Current Published Method
All samples selected for this study had adsorptions 
performed using the current method1 (Fig. 1). Equal volumes 
of patient serum and ficin-treated adsorbing RBCs were 
mixed and incubated at 37°C for 30 minutes to 1 hour with 
periodic mixing. The tube was centrifuged for 5 minutes, 
and the one-time adsorbed serum was harvested. Testing for 
adsorption effectiveness was performed in the same phases for 
which neat serum demonstrated reactivity and included the 
following: low-ionic-strength  saline (LISS)-37°C (ImmuAdd, 
Low Ionic Strength Medium; Immucor, Norcross, GA), LISS-
antihuman globulin (AHG), and PEG-AHG. Tubes were 
incubated at 37°C for 15 minutes for PEG and 20 minutes for 
LISS-AHG. After washing four times with saline, two drops 
of anti-IgG (Immucor) were added to each tube, and the tubes 
were centrifuged and read for agglutination. Testing that 
showed reactivity was followed with additional adsorptions. 
Adsorption was repeated by transferring the one-time 
adsorbed serum to another fresh aliquot of ficin-treated RBCs 
for a second adsorption. If necessary, a maximum of three 
total adsorptions were performed.
Adsorption Using the Modified 1:3 Method
Adsorption using the modified method was similar to that 
using the current method except the initial serum-to-cell ratio 
was modified to a ratio of one part patient’s serum to three 
parts RBCs (1:3 method; Fig. 2). The same adsorbing RBCs 
used in the original case workup, if adsorbed with allogeneic 
RBCs, were ficin-treated and dispensed into three separate 
12 × 75-mm test tubes. Using a plastic Pasteur pipette, for 
every three drops of RBCs, one drop of patient’s serum was 
added to yield a ratio of one part serum to three parts RBCs in 
each tube (1:3 ratio). The cell-serum mixture was mixed and 
incubated at 37°C for 1 hour with mixing every 10 minutes. 
An hour of incubation was allowed to best mimic the total 
adsorption time possible for a routine three-time adsorption. 
The three tubes were centrifuged for 5 minutes, and the 
adsorbed serum from all three tubes was combined into a 
single test tube. Three separate adsorbing tubes, as opposed to 
only one, were created to best mimic the adsorption conditions 
used when performing a three-time adsorption following the 
current published method. Adsorptions using the modified 1:3 
method were performed within 1 to 9 days after the original 
antibody workup (average, 3 days). Samples were stored at 2° 
to 4°C if testing was to be performed within 5 days. Samples 
were frozen if testing was to be performed longer than 5 days 
after the original antibody workup.
Testing of Adsorbed Serum from the 1:3 Method
The adsorbed serum was tested against screening 
cells if the original adsorbed patient sample demonstrated 
no underlying alloantibodies and against the selected cell 
panel used for the original antibody workup if the original 
patient sample demonstrated underlying alloantibodies. If 
alloantibody reactivity was detected with screening cells, a 
full panel and selected cells were tested to make identification. 
Testing was performed in the same phases that showed 
reactivity in the original case and included the following: 
LISS-37°C, LISS-AHG, and PEG-AHG. The effectiveness 
of the 1:3 method was then compared with previous results 
obtained from standard adsorption testing.
Statistics
Adsorption results of the 1:3 method were compared 
with those of the current method. If present, reactivity of each 
alloantibody in the adsorbed serum was scored for each method 
using the published scoring system.1 Data were statistically 
analyzed using the paired t test. The level of significance was 
established at a probability value of less than 0.05.
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Fig. 1 Current adsorption procedure.
30- to 60-minute 
incubation
30- to 60-minute 
incubation
30- to 60-minute 
incubation
Time* per procedure = 105–195 minutes
*Time for tests performed between adsorptions is not included.
1 part serum is  
added to 1 part  
red blood cells.
First tube is spun for  
5 minutes and serum  
is added to second 
tube containing equal 
part of red blood cells.
Second tube is spun for 
5 minutes and serum  
is added to third tube 
containing equal part 
of red blood cells.
Third tube is spun for  
5 minutes and 
adsorbed serum is 
tested for adsorption 
effectiveness.
Fig. 2 Modified 1:3 adsorption procedure.
1 part serum is added to 3 parts 
red blood cells in 3 tubes at the 
same time.
Time per procedure = 65 minutes
A 60-minute incubation time is allowed. 
Tubes are spun and the adsorbed serum 
from all the tubes is recombined.  
Adsorbed serum is then tested for 
adsorption effectiveness. 
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Results
Results of the 1:3 method showed 48 of 58 samples 
(83%) successfully adsorbed, matching the current method 
(Table 1). Of those 48 samples with successful adsorptions, 
20 (34.5%) were known from previous testing to contain 
alloantibodies. Eight samples failed to be fully adsorbed by 
either method. Three samples (26, 27, and 28) demonstrated 
underlying alloantibodies (two anti-E, one anti-f) with only 
the 1:3 method. Two samples (57 and 58), which previously 
were successfully adsorbed using autologous RBCs, failed 
to adsorb using allogeneic RBCs with both the current and 
1:3 methods on parallel testing. Two samples (30 and 39) 
contained underlying IgG antibodies of unknown specificity. 
In the 20 samples known to contain underlying alloantibodies, 
the 1:3 method demonstrated the same antibody specificities 
and comparable reaction strengths as the current method (p 
= 0.82), with one sample (38) showing a stronger reaction by 
the 1:3 method than by the current method (Table 2). Sample 
30 was reactive 1+ LISS-AHG with three of nine panel cells. 
Sample 39 was reactive 2+ LISS-AHG and PEG-AHG with 
four of eight panel cells.
Discussion
An important component of pretransfusion testing is to 
detect clinically significant alloantibodies.2 Patients with warm 
autoantibodies in their serum present a unique and challenging 
problem because the autoantibodies are broadly reactive, 
reacting with almost all RBCs tested. Warm autoantibodies 
are the most common cause of autoimmune hemolytic anemia 
(AIHA), with the incidence of these antibodies increasing with 
patient age.3 Although hemolytic transfusion reactions can 
occur when patients with clinically significant alloantibodies 
are transfused with RBCs carrying antigens corresponding 
to the alloantibodies,4 acute reactions are unlikely when RBC 
incompatibility is caused by autoantibody alone. Survival 
of transfused RBCs is generally the same as survival of the 
patient’s own RBCs, and transfusion can be expected to have 
significant temporary benefit.3,5,6
Patients with AIHA can have autoantibodies present 
in their serum. Warm autoantibodies can cause serologic 
anomalies including spontaneous agglutination that can 
result in discrepant ABO and Rh testing. More importantly, 
warm-reactive autoantibodies can mask the presence of 
clinically significant alloantibodies. Published data indicate 
that alloantibodies were detected in 209 of 647 serum samples 
(32%) of patients with AIHA.7 Undetected alloantibodies 
may cause increased hemolysis after transfusion, which can 
be falsely attributed to an increase in the severity of AIHA.3,8 
Furthermore, although fatalities caused by undetected 
clinically significant alloantibodies have declined in recent 
years,9 the detection of these alloantibodies is still necessary to 
prevent serious outcomes. When blood transfusion is ordered 
for a patient with autoantibodies in the serum, specialized 
serologic testing including adsorption studies, patient 
phenotyping, and eluate testing are helpful.10 A knowledge of 
the patient’s complete phenotype is useful to predict which 
clinically significant alloantibodies can potentially be present 
in the patient’s serum.
One of the most important testing procedures for a 
patient with AIHA, especially if the patient has a history 
of pregnancy or transfusion, is adsorption testing to 
remove autoantibody from the patient’s serum and allow 
for the detection and identification of clinically significant 
alloantibodies.1 Adsorption using autologous RBCs is the best 
procedure to detect clinically significant antibodies. However, 
autoadsorption should not be performed on samples from 
patients who have been recently transfused because transfused 
donor RBCs might adsorb alloantibodies, resulting in a falsely 
negative test result.
For patients with recent transfusions, the use of allogeneic 
RBCs is helpful in adsorbing autoantibodies, leaving behind 
alloantibodies in the adsorbed serum.1 If the patient’s 
phenotype is known, one allogeneic adsorbing cell can be 
selected to match the patient’s phenotype.1 The selection 
of cells is made easier by enzyme treating the allogeneic 
absorbing cells to destroy the MNS and Duffy antigens.1 When 
the patient’s phenotype is unknown, differential adsorption 
can be performed using group O RBCs of three different Rh 
phenotypes: R1R1, R2R2, and rr; one cell should lack the Jka 
antigen, and another should lack the Jkb antigen.1 Aliquots 
from each Rh phenotype are prepared and three separate 
adsorptions are performed, one with each Rh phenotype. 
Adsorbed serum from each adsorption can only be used to rule 
out alloantibodies corresponding to the antigens lacking on 
each adsorbing RBC phenotype. For example, R2R2 Jk(a–b+)-
adsorbing RBCs can be used to rule out alloantibodies specific 
for C, e, f, and Jka and not D, E, c, or Jkb.
Adequate testing to detect alloantibodies in the serum of a 
patient with autoantibodies may take 4 to 6 hours. Adsorption 
testing using the current method1 is time consuming and often 
results in delay of patient transfusion. Also, should routine 
allogeneic adsorption fail to remove alloantibody reactivity, 
a PEG-allogeneic adsorption should be performed.11 PEG-
allogeneic adsorption is a faster adsorption method involving 
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Underlying alloantibodies detected by 
current method
Underlying alloantibodies 
detected by 1:3 adsorption 
method
1:3 method successful at removing autoantibody 
reactivity?
1 X 1 None None Yes 
2 X 2 None None Yes
3 X 2 None None Yes
4 X 3 None None Yes
5 X 2 None None Yes
6 X 1 None None Yes
7 X 3 None None Yes 
8 X 3 None None Yes
9 X 1 None None Yes
10 X 1 None None Yes
11 X 1 None None Yes
12 X 2 None None Yes
13 X 2 None None Yes
14 X 1 None None Yes
15 X 3 None None Yes
16 X 1 None None Yes
17 X 2 None None Yes
18 X 1 None None Yes
19 X 2 None None Yes
20 X 1 None None Yes
21 X 2 None None Yes
22 X 1 None None Yes
23 X 2 None None Yes
24 X 3 None None Yes
25 X 3 None None Yes
26 X 3 None Anti-E Yes
27 X 3 None Anti-f Yes
28 X 2 None Anti-E Yes
29 X 3 Anti-E Anti-E Yes
30 X 3 Anti-K, unknown IgG Anti-K, unknown IgG Yes
31 X 3 Anti-E Anti-E Yes
32 X 1 Anti-E Anti-E Yes
33 X 2 Anti-E Anti-E Yes
34 X 3 Anti-E Anti-E Yes
35 X 3 Anti-E Anti-E Yes
36 X 3 Anti-E Anti-E Yes
37 X 2 Anti-Jka Anti-Jka Yes
38 X 1 Anti-E Anti-E Yes
39 X 3 Unknown IgG Unknown IgG Yes
40 X 1 Anti-S Anti-S Yes
41 X 2 Anti-K Anti-K Yes
42 X 1 Anti-E Anti-E Yes
43 X 1 Anti-E, -Jkb, -S Anti-E, -Jkb, -S Yes
44 X 2 Anti-E, -C Anti-E, -C Yes
45 X 1 Anti-E Anti-E Yes
46 X 2 Anti-E Anti-E Yes
47 X 1 Anti-C, -E Anti-C, -E Yes
48 X 2 Anti-C, -K, -S Anti-C, -K, -S Yes
49 X (PEG) 2 None NA No - required PEG adsorption
50 X (PEG) 2 None NA No - required PEG adsorption
51 X (PEG) 2 None NA No - required PEG adsorption
52 X (PEG) 3 Unknown IgG NA No - required PEG adsorption
53 X (PEG) 3 Anti-C, -K, -Jkb, -M, -S NA No - required PEG adsorption
54 X (PEG) 3 None NA No - required PEG adsorption
55 X (PEG) 3 None NA No - required PEG adsorption
56 X (PEG) 2 None NA No - required PEG adsorption
57 X 2 None NA No - only autologous adsorption successful
58 X 3 Anti-s NA No - only autologous adsorption successful
PEG = polyethylene glycol.
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adsorption with one part RBCs, one part PEG, and one part 
serum for 15 minutes up to a total of three adsorptions. After 
adsorption, four to six drops of PEG-adsorbed serum are used 
to test with each panel cell originally reactive with neat serum. 
Additional enhancement media are not needed because of 
the PEG present in the PEG-adsorbed serum. Although 
PEG adsorption is a faster procedure than routine allogeneic 
adsorption, there is the risk that weak alloantibodies will 
not be detected.12 Knowing sooner whether PEG adsorption 
is necessary aids in reducing the overall turnaround time of 
making blood available for transfusion.
This study showed that the 1:3 method gave results 
comparable to those of the current adsorption method, and 
in much less time, for those samples that originally required 
more than one adsorption. Of the 58 serum samples selected 
at random for this study, 48 were successfully adsorbed using 
both the current and 1:3 methods. Of these 48 samples, 
20 (34.5%) contained underlying alloantibodies, which is 
consistent with the average of 32 percent from published 
data.7 In all 20 samples with underlying alloantibodies, the 
1:3 method demonstrated the same antibody specificities and 
reaction strengths as the current method, with one sample 
yielding stronger alloantibody reactivity in the 1:3 method. 
Eight samples that failed to be adsorbed by the current method 
also failed with the 1:3 method. The modified 1:3 method 
detected underlying alloantibodies in three samples that were 
not detected using the current method. Two samples that 
successfully adsorbed in previous testing using autologous 
RBCs failed to adsorb by the 1:3 method using allogeneic 
adsorbing RBCs. Further parallel adsorption testing using 
two separate allogeneic adsorbing RBCs showed both samples 
failed to adsorb using both the current and 1:3 methods. An 
explanation could not be found in either of the two samples 
that successfully autoadsorbed, but failed to alloadsorb by 
routine methods, as to why only autologous adsorption could 
remove autoantibody reactivity.
Other studies13–15 reported that reductions in adsorption 
incubation times to as little as 10 minutes are equally effective 
as currently accepted standard methods. Possible future studies 
could combine this 1:3 method with a shortened incubation 
time to evaluate whether autoantibodies could still be effectively 
removed without adverse impact on the final results.
Summary
Standard adsorptions can require 4 to 6 hours; the 1:3 
method required approximately 1 to 1.5 hours for the entire 
adsorption process. In conclusion, this study showed the 1:3 
method of using one part patient’s serum to three parts RBCs 
to be time efficient as well as effective for quick removal of 
autoantibodies while allowing for the detection of underlying 
alloantibodies.
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* Reaction based on reactivity at the strongest phase (either  low-ionic-
strength saline [LISS]-antihuman globulin [AHG] or polyethylene glycol 
[PEG]-AHG).
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